[Comparative efficacy of annual and semi-annual doses of ivermectin or diethylcarbamazine for the prevention of lymphatic filariasis].
Identifieur interne : 00D059 ( Main/Exploration ); précédent : 00D058; suivant : 00D060[Comparative efficacy of annual and semi-annual doses of ivermectin or diethylcarbamazine for the prevention of lymphatic filariasis].
Auteurs : J L Cartel [Polynésie française] ; A. Spiegel ; L. Nguyen ; J P Moulia-Pelat ; P M Martin ; J F RouxSource :
- Revue d'epidemiologie et de sante publique [ 0398-7620 ] ; 1992.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Humains, Ivermectine (administration et posologie), Ivermectine (effets indésirables), Mâle, Méthode en double aveugle, Relation dose-effet des médicaments, Wuchereria bancrofti, Éléphantiasis (traitement médicamenteux).
- MESH :
- administration et posologie : Diéthylcarbamazine, Ivermectine.
- effets indésirables : Diéthylcarbamazine, Ivermectine.
- traitement médicamenteux : Éléphantiasis.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Humains, Mâle, Méthode en double aveugle, Relation dose-effet des médicaments, Wuchereria bancrofti.
English descriptors
- KwdEn :
- Adolescent, Adult, Animals, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Dose-Response Relationship, Drug, Double-Blind Method, Elephantiasis (drug therapy), Humans, Ivermectin (administration & dosage), Ivermectin (adverse effects), Male, Middle Aged, Wuchereria bancrofti.
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Ivermectin.
- chemical , adverse effects : Diethylcarbamazine, Ivermectin.
- drug therapy : Elephantiasis.
- Adolescent, Adult, Animals, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Male, Middle Aged, Wuchereria bancrofti.
Abstract
A double blind randomized trial was performed on 58 healthy Polynesian Wuchereria bancrofti carriers, they were randomly allocated to treatments with repeated annual or semi-annual doses of ivermectin 100 mcg/kg or diethylcarbamazine (DEC) 3 mg/kg, or with repeated annual doses of DEC 6 mg/kg. After the 12-month treatment, the clearance of microfilaremia was complete in 7 of the 23 carriers treated with ivermectin and in 3 of the 35 treated with DEC. Nine months after that treatment, the lowest mean microfilaremia was observed in the carriers treated with 3 successive semi-annual doses of DEC 3 mg/kg. Adverse reactions were comparable in carriers treated with ivermectin and in those treated with DEC, and did not interfere with daily activities of treated subjects.
PubMed: 1480807
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 005A10
- to stream PubMed, to step Curation: 005A10
- to stream PubMed, to step Checkpoint: 005A10
- to stream Ncbi, to step Merge: 001845
- to stream Ncbi, to step Curation: 001845
- to stream Ncbi, to step Checkpoint: 001845
- to stream Main, to step Merge: 00DB09
- to stream Main, to step Curation: 00D059
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Comparative efficacy of annual and semi-annual doses of ivermectin or diethylcarbamazine for the prevention of lymphatic filariasis].</title><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Tahiti, Polynésie Française.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Médicales Louis Malardé, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Spiegel, A" sort="Spiegel, A" uniqKey="Spiegel A" first="A" last="Spiegel">A. Spiegel</name></author><author><name sortKey="Nguyen, L" sort="Nguyen, L" uniqKey="Nguyen L" first="L" last="Nguyen">L. Nguyen</name></author><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Roux, J F" sort="Roux, J F" uniqKey="Roux J" first="J F" last="Roux">J F Roux</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1480807</idno><idno type="pmid">1480807</idno><idno type="wicri:Area/PubMed/Corpus">005A10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005A10</idno><idno type="wicri:Area/PubMed/Curation">005A10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005A10</idno><idno type="wicri:Area/PubMed/Checkpoint">005A10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005A10</idno><idno type="wicri:Area/Ncbi/Merge">001845</idno><idno type="wicri:Area/Ncbi/Curation">001845</idno><idno type="wicri:Area/Ncbi/Checkpoint">001845</idno><idno type="wicri:doubleKey">0398-7620:1992:Cartel J:comparative:efficacy:of</idno><idno type="wicri:Area/Main/Merge">00DB09</idno><idno type="wicri:Area/Main/Curation">00D059</idno><idno type="wicri:Area/Main/Exploration">00D059</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Comparative efficacy of annual and semi-annual doses of ivermectin or diethylcarbamazine for the prevention of lymphatic filariasis].</title><author><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name><affiliation wicri:level="1"><nlm:affiliation>Institut Territorial de Recherches Médicales Louis Malardé, Tahiti, Polynésie Française.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">Polynésie française</country><wicri:regionArea>Institut Territorial de Recherches Médicales Louis Malardé, Tahiti</wicri:regionArea><wicri:noRegion>Tahiti</wicri:noRegion></affiliation></author><author><name sortKey="Spiegel, A" sort="Spiegel, A" uniqKey="Spiegel A" first="A" last="Spiegel">A. Spiegel</name></author><author><name sortKey="Nguyen, L" sort="Nguyen, L" uniqKey="Nguyen L" first="L" last="Nguyen">L. Nguyen</name></author><author><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name></author><author><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name></author><author><name sortKey="Roux, J F" sort="Roux, J F" uniqKey="Roux J" first="J F" last="Roux">J F Roux</name></author></analytic><series><title level="j">Revue d'epidemiologie et de sante publique</title><idno type="ISSN">0398-7620</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Elephantiasis (drug therapy)</term><term>Humans</term><term>Ivermectin (administration & dosage)</term><term>Ivermectin (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Humains</term><term>Ivermectine (administration et posologie)</term><term>Ivermectine (effets indésirables)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Relation dose-effet des médicaments</term><term>Wuchereria bancrofti</term><term>Éléphantiasis (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Éléphantiasis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Animals</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Animaux</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Relation dose-effet des médicaments</term><term>Wuchereria bancrofti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A double blind randomized trial was performed on 58 healthy Polynesian Wuchereria bancrofti carriers, they were randomly allocated to treatments with repeated annual or semi-annual doses of ivermectin 100 mcg/kg or diethylcarbamazine (DEC) 3 mg/kg, or with repeated annual doses of DEC 6 mg/kg. After the 12-month treatment, the clearance of microfilaremia was complete in 7 of the 23 carriers treated with ivermectin and in 3 of the 35 treated with DEC. Nine months after that treatment, the lowest mean microfilaremia was observed in the carriers treated with 3 successive semi-annual doses of DEC 3 mg/kg. Adverse reactions were comparable in carriers treated with ivermectin and in those treated with DEC, and did not interfere with daily activities of treated subjects.</div></front></TEI><affiliations><list><country><li>Polynésie française</li></country></list><tree><noCountry><name sortKey="Martin, P M" sort="Martin, P M" uniqKey="Martin P" first="P M" last="Martin">P M Martin</name><name sortKey="Moulia Pelat, J P" sort="Moulia Pelat, J P" uniqKey="Moulia Pelat J" first="J P" last="Moulia-Pelat">J P Moulia-Pelat</name><name sortKey="Nguyen, L" sort="Nguyen, L" uniqKey="Nguyen L" first="L" last="Nguyen">L. Nguyen</name><name sortKey="Roux, J F" sort="Roux, J F" uniqKey="Roux J" first="J F" last="Roux">J F Roux</name><name sortKey="Spiegel, A" sort="Spiegel, A" uniqKey="Spiegel A" first="A" last="Spiegel">A. Spiegel</name></noCountry><country name="Polynésie française"><noRegion><name sortKey="Cartel, J L" sort="Cartel, J L" uniqKey="Cartel J" first="J L" last="Cartel">J L Cartel</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00D059 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00D059 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:1480807
|texte= [Comparative efficacy of annual and semi-annual doses of ivermectin or diethylcarbamazine for the prevention of lymphatic filariasis].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:1480807" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |